Gilead Sciences Inc - Asset Resilience Ratio
Gilead Sciences Inc (GILD) has an Asset Resilience Ratio of 17.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Gilead Sciences Inc's Asset Resilience Ratio has changed over time. Check Gilead Sciences Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Gilead Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Gilead Sciences Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.61 Billion | 17.97% |
| Total Liquid Assets | $10.61 Billion | 17.97% |
Asset Resilience Insights
- Good Liquidity Position: Gilead Sciences Inc maintains a healthy 17.97% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Gilead Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Gilead Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.10% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 7.83% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Annual Asset Resilience Ratio for Gilead Sciences Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Gilead Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.67% | $1.58 Billion | $58.99 Billion | +0.78pp |
| 2023-12-31 | 1.90% | $1.18 Billion | $62.12 Billion | +0.36pp |
| 2022-12-31 | 1.54% | $973.00 Million | $63.17 Billion | -0.20pp |
| 2021-12-31 | 1.74% | $1.18 Billion | $67.95 Billion | -0.32pp |
| 2020-12-31 | 2.06% | $1.41 Billion | $68.41 Billion | -18.58pp |
| 2019-12-31 | 20.64% | $12.72 Billion | $61.63 Billion | +1.56pp |
| 2018-12-31 | 19.08% | $12.15 Billion | $63.67 Billion | -6.42pp |
| 2017-12-31 | 25.50% | $17.92 Billion | $70.28 Billion | +19.07pp |
| 2016-12-31 | 6.43% | $3.67 Billion | $56.98 Billion | +3.05pp |
| 2015-12-31 | 3.39% | $1.76 Billion | $51.84 Billion | +3.10pp |
| 2014-12-31 | 0.29% | $101.00 Million | $34.66 Billion | +0.21pp |
| 2013-12-31 | 0.08% | $19.00 Million | $22.58 Billion | -0.19pp |
| 2012-12-31 | 0.28% | $58.56 Million | $21.24 Billion | +0.18pp |
| 2011-12-31 | 0.10% | $16.49 Million | $17.30 Billion | -10.18pp |
| 2010-12-31 | 10.27% | $1.19 Billion | $11.59 Billion | +6.31pp |
| 2009-12-31 | 3.96% | $384.02 Million | $9.70 Billion | -0.81pp |
| 2008-12-31 | 4.77% | $330.76 Million | $6.94 Billion | +1.27pp |
| 2007-12-31 | 3.49% | $203.89 Million | $5.83 Billion | +0.54pp |
| 2006-12-31 | 2.96% | $120.84 Million | $4.09 Billion | -39.61pp |
| 2005-12-31 | 42.56% | $1.60 Billion | $3.77 Billion | -2.57pp |
| 2004-12-31 | 45.14% | $973.13 Million | $2.16 Billion | +12.19pp |
| 2003-12-31 | 32.95% | $512.28 Million | $1.55 Billion | +7.69pp |
| 2002-12-31 | 25.26% | $325.44 Million | $1.29 Billion | -32.53pp |
| 2001-12-31 | 57.80% | $459.36 Million | $794.79 Million | +11.26pp |
| 2000-12-31 | 46.54% | $315.59 Million | $678.10 Million | -10.09pp |
| 1999-12-31 | 56.63% | $247.38 Million | $436.81 Million | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more